Skip to main content
  • Register
  • Help
  • Contact us

Avacta Group plc (AVCT) Ordinary Shares 10p

Sell:232.00p Buy:234.00p 0 Change: 13.00p (5.28%)
FTSE AIM 100:0.09%
Market closed Prices as at close on 23 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:232.00p
Buy:234.00p
Change: 13.00p (5.28%)
Market closed Prices as at close on 23 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:232.00p
Buy:234.00p
Change: 13.00p (5.28%)
Market closed Prices as at close on 23 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Contact details

Address:
Unit 20, Ash Way
WETHERBY
LS23 7FA
United Kingdom
Telephone:
+44 (01904) 217070
Website:
https://www.avacta.com/key-information

Important dates

Future events
There are no future events available.
Past events
Final results 22 April 2021 22/04/21
Interim results 28 September 2020 28/09/20
Trading Announcement 22 July 2020 22/07/20
General meeting 24 June 2020 24/06/20
AGM 22 June 2020 22/06/20
Annual report 28 May 2020 28/05/20
Final results 06 May 2020 06/05/20
Interim results 06 May 2020 06/05/20

General stock information

EPIC:
AVCT
ISIN:
GB00BYYW9G87
Market cap:
£590.41 million
Shares in issue:
253.40 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Alastair Smith
    Chief Executive Officer, Executive Director
  • Tony Gardiner
    Group Chief Financial Officer
  • Neil Bell
    Chief Development Officer
  • Jose Saro
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.